News | December 13, 2025
EMA backs Eylea 8 mg for retinal vein occlusion
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
The companies aim to expand treatment options for millions living with metabolic disorders
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
Subscribe To Our Newsletter & Stay Updated
